ATYR aTyr Pharmaceuticals: רווח נקי למניה ב-12 החודשים האחרונים

The market trend for aTyr Pharma, Inc. (ATYR) shown on this price chart reflects an EPS TTM of 35.50. aTyr Pharma, Inc. (ATYR) specializes in pulmonary fibrosis therapy using the proprietary protein Efzofitimod. A system of grants and options ensures the stability of the scientific team, preventing talent attrition. The business relies on developing cutting-edge drugs against severe inflammation through deep research into the body's biological mechanisms.
aTyr Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (ATYR)

The annual growth rate of earnings per share (TTM) measures the actual accounting expansion of the business, neutralizing short-term noise and one-time write-offs over a twelve-month cycle. An analysis of the rolling YoY earnings per share change for aTyr Pharma, Inc. (ATYR) demonstrates the efficiency of patent capitalization coupled with low production costs, confirming the high-margin potential of the immunomedicine model.